Arvinas 10-Q: $558.9M Cash Funds Operations Into 2H 2028 After $53.9M Q3 Loss
ARVN is trading near its 52-week low of $6.74 (5.2% above the low) on elevated volume (2.2× avg).
Summary
Arvinas ended Q3 2026 with $558.9M in cash and securities, enough to fund operations into the second half of 2028, while posting a $53.9M quarterly loss on $0.5M of royalty revenue. The 10-Q also discloses that the ARV-102 PSP trial remains on FDA clinical hold.
Key Events · Earnings and Guidance · ARVN
-
Q3 Loss of $53.9M on $0.5M Revenue
Third-quarter 2026 net loss was $53.9M, or $0.82 per share, versus a $35.1M loss a year earlier; revenue was $0.5M of sales-based royalties under the Rigel License Agreement.
-
Cash of $558.9M, Runway Into 2H 2028
Cash, cash equivalents, restricted cash and marketable securities totaled $558.9M at September 30, 2026, which management says funds planned operating expenses and capital expenditures into the second half of 2028.
-
Nine-Month Operating Cash Use Halved
Net cash used in operations was $127.9M for the nine months ended September 30, 2026, versus $243.4M a year earlier, helped by $57.9M of nine-month net income and lower spending.
-
ARV-102 PSP Trial Still on FDA Hold
The planned Phase 1b trial of ARV-102 in progressive supranuclear palsy remains on clinical hold pending FDA review; Arvinas plans an EU CTA in Q4 2026 and a UK CTA in Q1 2027, with trial initiation in 2027.
Analysis · ARVN · Life Sciences
The headline loss was already out this morning, but the 10-Q is where the balance sheet and runway live: $558.9M of cash, restricted cash and marketable securities at September 30, which management says funds planned operations into the second half of 2028. For a clinical-stage company with no product revenue of its own, that runway is the core of the thesis — VEPPANU is now Rigel's to commercialize, and Arvinas booked only $0.5M of sales-based royalties in the quarter. Cost cuts are doing real work: R&D fell to $46.9M from $64.7M and G&A to $12.6M from $21.0M year over year, and nine-month operating cash use improved to $127.9M from $243.4M. The offset is that the pipeline now carries the story, and one program is stalled — the ARV-102 Phase 1b trial in PSP is on clinical hold while the FDA reviews, pushing the EU and UK trial starts to 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARVN was trading at $7.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $463.6M. The 52-week trading range was $6.74 to $14.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.